

# Correspondence Between Patients' and Neurologists' Satisfaction With Treatment in Patients With CIDP: Results from a Real-World International Survey

Sandra Paci, PhD<sup>1</sup>, Febe Brackx, Ir, MSc<sup>2</sup>, Clémence Arvin-Berod, PharmD<sup>1</sup>, Lucas Van de Veire, MA<sup>2</sup>, Yasmin Taylor, MBiol<sup>3</sup>, Jack Wright, MSc<sup>3</sup>, Sarah Dewilde, PhD<sup>2</sup>

argenx SHE  
Adelphi  
ADELPHI REAL WORLD


SA23

<sup>1</sup>argenx BV, Ghent, Belgium; <sup>2</sup>Services in Health Economics (SHE) BV, Brussels, Belgium; <sup>3</sup>Adelphi Real World, Bollington, UK

## BACKGROUND | METHODS

- Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) is a rare progressive autoimmune disorder affecting the peripheral nerves, characterized by muscle weakness and sensory deficits.
- Real-world evidence reported by patients and their physicians can help ascertain the needs and burden associated with CIDP.
- We assessed the level of alignment between patient- and physician-reported treatment satisfaction using matched patient-physician data from Adelphi's CIDP Disease Specific Programme™.

- The survey was conducted in France, Germany, Italy, and Spain between April 2022 and April 2023 (n=199), with treatment satisfaction data available for 152 patients.
- Data on patients' satisfaction with overall treatment, symptom control and treatment convenience was included when all three questions were answered.
- Patients and physicians completed slightly different Likert scales to assess treatment satisfaction: *completely satisfied / satisfied / neither / dissatisfied / completely dissatisfied* (patients) versus *very satisfied / somewhat satisfied / neither / somewhat dissatisfied / very dissatisfied* (physicians). For correspondence analyses, it was assumed these scales are the same.



## RESULTS

### 1. Demographics

- The mean age in our sample was 52.4 (SD 12.0) years; 56.8% of patients were male, and 69.8% had typical CIDP. Out of 199 patients, 82.4% were prescribed treatment. Corticosteroids were the most prescribed treatment type (40.9%) (Table 1).

TABLE 1 Patient characteristics (n=199)


Sex, N (%)	Male	113 (56.8%)
Age (years)	Female	86 (43.2%)
Country, N (%)	France	32 (16.1%)
	Germany	93 (46.7%)
	Italy	34 (17.1%)
	Spain	40 (20.1%)
CIDP type, N (%)	Typical CIDP	139 (69.8%)
	Atypical CIDP	60 (30.2%)
Prescribed treatment, N (%)		164 (82.4%)
	Immunoglobulins (no corticosteroid)	49 (29.9%)
	Corticosteroids (no immunoglobulin)	67 (40.9%)
	Both immunoglobulins & corticosteroids	13 (7.9%)
	Other*	35 (21.3%)
Time on prescribed treatment at time of survey (n=161)	Median (IQR) years	1.9 (0.8-3.3)

\*Biologics: 12.8%; Non-steroidal immunosuppressants: 6.7%; Neuropathic pain therapies: 1.8%; Plasmapheresis: 0.6%

### 2. Patient satisfaction with treatment

- The majority of patients were completely satisfied or satisfied with treatment overall (71.7%) and in terms of symptom control (68.6%). Almost half were less than satisfied with treatment convenience (47.1%) (Figure 1).

FIGURE 1 Patient satisfaction with treatment in terms of... (n=152)



- High usage of corticosteroids despite the approval of Ig indicates a potential unmet need for new treatments.

- Treatment satisfaction decreased with increasing disability. Across disability levels, physicians reported higher satisfaction than patients.

- Physician and patients were not aligned in their satisfaction with treatment in over half of the cases; physicians were more likely to report a higher satisfaction level than patients.

- This points to potential gaps in perception that may impact patients' management, adherence and quality of life.

### KEY TAKEAWAYS

PRESENTED AT THE PROFESSIONAL SOCIETY FOR HEALTH ECONOMICS AND OUTCOMES RESEARCH (ISPOR); NOV 9 - NOV 12, 2025; GLASGOW, SCOTLAND, UK

ABBREVIATIONS: CIDP: Chronic Inflammatory Demyelinating Polyradiculoneuropathy; N: Sample size, SD: standard deviation, IQR: Interquartile Range.

ACKNOWLEDGMENTS: This study used data from the Adelphi Real World CIDP DSP, an independently conducted survey. Argenx were one of multiple subscribers to the DSP, and funded the analysis described here. The material in this poster has not been previously presented or published. CA and SP are employees of and hold stock in Argenx. FB, LV and SD are paid consultants for and receive grant support from Argenx. YT and JW are employees of Adelphi Real World.

SCAN ME

